Uptake of pre-exposure prophylaxis (PrEP)—a preventive medication that reduces the risk of acquiring HIV through sex and injection drug use, has been slow, despite its high efficacy and recommended use for those at risk. Furthermore, disparities in access and use exist along racial, ethnic, and gender lines. The Centers for Disease Control and Prevention (CDC) estimates that in 2020 about 300,800 people were prescribed PrEP, representing only 25% of those with an indicated need for the medication.
